Long noncoding RNA FEZF1‐AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR‐142/HIF‐1α and miR‐133a/EGFR upon hypoxia/normoxia
Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment‐resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR‐142/HIF‐1α and miR‐133a/EGFR could modulate PC cell proliferation under...
Saved in:
Published in | Journal of cellular physiology Vol. 234; no. 9; pp. 15407 - 15419 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.09.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment‐resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR‐142/HIF‐1α and miR‐133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1‐AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR‐142 and miR‐133a; thus, we hypothesized that FEZF1‐AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1‐AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR‐142/HIF‐1α axis under hypoxic condition; however, FEZF1‐AS1 failed to affect the protein levels of HIF‐1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1‐AS1 could target miR‐133a to inhibit its expression; under the normoxic condition, FEZF1‐AS1 exerted its effect on PC cell lines through miR‐133a/EGFR axis. Taken together, FEZF1‐AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines.
FEZF1‐AS1 could promote pancreatic cancer (PC) cell proliferation and invasion through miR‐142/HIF1A axis under hypoxic condition while through miR‐133a/EGFR axis under normoxic condition. FEZF1‐AS1 might be a promising target in controlling the proliferation and proliferation of PC cell lines. |
---|---|
AbstractList | Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment-resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR-142/HIF-1α and miR-133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1-AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR-142 and miR-133a; thus, we hypothesized that FEZF1-AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1α axis under hypoxic condition; however, FEZF1-AS1 failed to affect the protein levels of HIF-1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1-AS1 could target miR-133a to inhibit its expression; under the normoxic condition, FEZF1-AS1 exerted its effect on PC cell lines through miR-133a/EGFR axis. Taken together, FEZF1-AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines. Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment‐resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR‐142/HIF‐1α and miR‐133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1‐AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR‐142 and miR‐133a; thus, we hypothesized that FEZF1‐AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1‐AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR‐142/HIF‐1α axis under hypoxic condition; however, FEZF1‐AS1 failed to affect the protein levels of HIF‐1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1‐AS1 could target miR‐133a to inhibit its expression; under the normoxic condition, FEZF1‐AS1 exerted its effect on PC cell lines through miR‐133a/EGFR axis. Taken together, FEZF1‐AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines. FEZF1‐AS1 could promote pancreatic cancer (PC) cell proliferation and invasion through miR‐142/HIF1A axis under hypoxic condition while through miR‐133a/EGFR axis under normoxic condition. FEZF1‐AS1 might be a promising target in controlling the proliferation and proliferation of PC cell lines. Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment-resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR-142/HIF-1α and miR-133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1-AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR-142 and miR-133a; thus, we hypothesized that FEZF1-AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1α axis under hypoxic condition; however, FEZF1-AS1 failed to affect the protein levels of HIF-1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1-AS1 could target miR-133a to inhibit its expression; under the normoxic condition, FEZF1-AS1 exerted its effect on PC cell lines through miR-133a/EGFR axis. Taken together, FEZF1-AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines.Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment-resistant phenotype induced by the extent of hypoxic stress within the tumor tissue. According to previous studies, miR-142/HIF-1α and miR-133a/EGFR could modulate PC cell proliferation under hypoxic and normoxic conditions, respectively. In the present study, FEZF1-AS1, a recently described oncogenic long noncoding RNA, was predicted to target both miR-142 and miR-133a; thus, we hypothesized that FEZF1-AS1 might affect PC cell proliferation through these two axes under hypoxic or normoxic conditions. In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1α axis under hypoxic condition; however, FEZF1-AS1 failed to affect the protein levels of HIF-1α and VEGF under the normoxic condition, suggesting the existence of another signaling pathway under normoxic condition. As predicted by an online tool, FEZF1-AS1 could target miR-133a to inhibit its expression; under the normoxic condition, FEZF1-AS1 exerted its effect on PC cell lines through miR-133a/EGFR axis. Taken together, FEZF1-AS1 might be a promising target in controlling the aberrant proliferation and invasion of PC cell lines. |
Author | Luo, Zhen Li, Yi‐Xiong Lu, Ye‐Bin Han, Tong Ou, Zheng‐Lin Ji, Lian‐Dong Zhang, Min |
Author_xml | – sequence: 1 givenname: Zheng‐Lin surname: Ou fullname: Ou, Zheng‐Lin organization: Xiangya Hospital, Central South University – sequence: 2 givenname: Min surname: Zhang fullname: Zhang, Min organization: The Second Xiangya Hospital, Central South University – sequence: 3 givenname: Lian‐Dong surname: Ji fullname: Ji, Lian‐Dong organization: Xiangya Hospital, Central South University – sequence: 4 givenname: Zhen orcidid: 0000-0003-2444-5138 surname: Luo fullname: Luo, Zhen organization: The Third Xiangya Hospital, Central South University – sequence: 5 givenname: Tong surname: Han fullname: Han, Tong organization: The Second Xiangya Hospital, Central South University – sequence: 6 givenname: Ye‐Bin surname: Lu fullname: Lu, Ye‐Bin organization: Xiangya Hospital, Central South University – sequence: 7 givenname: Yi‐Xiong surname: Li fullname: Li, Yi‐Xiong email: liyixiong2011@hotmail.com organization: Xiangya Hospital, Central South University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30693518$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc9uEzEQxi1URNPCgRdAK3GBwzb-txv7GEXZtigCFODCxXIcO3G0a2_tXSA3HoFX4c4z8BA8Cd4kvVRw8ozn9332zFyAM-edBuA5glcIQjzeqfYKM8TYIzBCkE9yWhb4DIxSDeW8oOgcXMS4gxByTsgTcE5gyUmB2Aj8Wni3yZKf8mubouXbaVbNP1foz_cf0w8oa4NeW9XFrPU-pMxvnI82ZtKts8av-1p2OhWlU0HLzqpMpVCHTOm6HvDaGh1SwbuDxLovMg5Jtw2-32yzxi7TS4ji8c1tNUS_fx69j_eEyPH8ulpmfZtE233rv1k5dj40Q_AUPDayjvrZ6bwEn6r5x9lNvnh3fTubLnKFS8ZyWmBaQINKpCQxrFytkGbJuZhISBTSVGPDy4nhZMKxKYgxWpaI8QKVkK6gIZfg1dE3NXTX69iJxsahQ-m076PAaMIpLSEhCX35AN35Prj0O4Ex5oyyNPZEvThR_arRa9EG28iwF_d7ScD4CKjgYwzaCGW7wxi7IG0tEBTD5kXavDhsPileP1Dcm_6LPbl_tbXe_x8Ub2bvj4q_LOLA1A |
CitedBy_id | crossref_primary_10_2147_NSS_S385755 crossref_primary_10_2147_OTT_S235970 crossref_primary_10_1186_s12935_021_02125_1 crossref_primary_10_1016_j_canlet_2020_11_007 crossref_primary_10_1016_j_jare_2025_02_001 crossref_primary_10_3390_cancers15133486 crossref_primary_10_1016_j_prp_2019_152687 crossref_primary_10_1186_s13045_020_01030_w crossref_primary_10_1016_j_ejphar_2023_175535 crossref_primary_10_1089_dna_2024_0184 crossref_primary_10_1186_s12935_020_01370_0 crossref_primary_10_1007_s00018_019_03444_3 crossref_primary_10_1186_s12929_020_00654_x crossref_primary_10_1007_s11033_023_08370_z crossref_primary_10_1007_s11033_024_09802_0 crossref_primary_10_3390_ncrna6030027 crossref_primary_10_1016_j_prp_2023_154438 crossref_primary_10_2174_1566524022666220120123557 crossref_primary_10_3389_fonc_2021_765216 crossref_primary_10_3390_ijms22147261 crossref_primary_10_32604_or_2022_03553 crossref_primary_10_1111_cas_15388 crossref_primary_10_3390_cells9112353 crossref_primary_10_1016_j_bj_2021_03_005 crossref_primary_10_2147_OTT_S261461 crossref_primary_10_18632_aging_202960 crossref_primary_10_1007_s12672_022_00522_0 crossref_primary_10_1042_BSR20190754 |
Cites_doi | 10.3892/mmr.2015.3144 10.1038/onc.2015.325 10.1089/ars.2007.1628 10.18632/oncotarget.8834 10.1002/jcb.25988 10.2478/s11658-014-0212-6 10.1016/j.bbrc.2011.04.035 10.3892/ol.2013.1620 10.1093/ije/dyx232 10.1007/978-1-4939-3378-5_21 10.1016/j.cell.2011.07.014 10.1016/j.biopha.2017.08.057 10.1177/1535370214555665 10.1007/s11010-013-1795-3 10.1586/17474124.2016.1117386 10.1016/S0360-3016(00)00803-8 10.1242/bio.021774 10.1016/j.ctrv.2017.08.007 10.1097/MPA.0000000000000389 10.1038/s41419-017-0052-1 10.18632/oncotarget.7168 10.1016/j.biopha.2017.11.113 10.2174/187152011795677463 10.1186/s12943-017-0588-9 10.4238/gmr15048936 10.1177/1533034616665720 |
ContentType | Journal Article |
Copyright | 2019 Wiley Periodicals, Inc. |
Copyright_xml | – notice: 2019 Wiley Periodicals, Inc. |
DBID | AAYXX CITATION NPM 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 |
DOI | 10.1002/jcp.28188 |
DatabaseName | CrossRef PubMed Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed Genetics Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | PubMed Genetics Abstracts CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Biology |
EISSN | 1097-4652 |
EndPage | 15419 |
ExternalDocumentID | 30693518 10_1002_jcp_28188 JCP28188 |
Genre | article Journal Article |
GroupedDBID | --- -DZ -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 9M8 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDPE ABEFU ABEML ABIJN ABJNI ABPPZ ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACNCT ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AUFTA AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BQCPF BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ H~9 IH2 IX1 J0M JPC KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M56 MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MVM MXFUL MXSTM N04 N05 N9A NEJ NF~ NNB O66 O9- OHT OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RWR RX1 RYL S10 SAMSI SUPJJ SV3 TN5 TWZ UB1 UPT V2E V8K VQP W8V W99 WBKPD WH7 WIB WIH WIK WJL WNSPC WOHZO WQJ WRC WXSBR WYB WYISQ X7M XG1 XJT XOL XPP XSW XV2 Y6R YQT YZZ ZGI ZXP ZZTAW ~IA ~WT AAYXX ADXHL AETEA AEYWJ AGHNM AGQPQ AGYGG CITATION NPM PKN 7TK 7U7 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c2688-452450f161ca3f86bb1e833a57a03c1e4e2f967f93792f53ffea618951604b0f3 |
IEDL.DBID | DR2 |
ISSN | 0021-9541 1097-4652 |
IngestDate | Fri Jul 11 11:05:53 EDT 2025 Fri Jul 25 19:51:11 EDT 2025 Wed Feb 19 02:25:45 EST 2025 Thu Apr 24 23:06:46 EDT 2025 Tue Jul 01 01:32:00 EDT 2025 Wed Jan 22 16:38:31 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | miR-142/HIF-1α pancreatic cancer FEZF1-AS1 invasion miR-133a/EGFR |
Language | English |
License | 2019 Wiley Periodicals, Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2688-452450f161ca3f86bb1e833a57a03c1e4e2f967f93792f53ffea618951604b0f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-2444-5138 |
PMID | 30693518 |
PQID | 2229848518 |
PQPubID | 1006363 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2179446033 proquest_journals_2229848518 pubmed_primary_30693518 crossref_citationtrail_10_1002_jcp_28188 crossref_primary_10_1002_jcp_28188 wiley_primary_10_1002_jcp_28188_JCP28188 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | September 2019 2019-09-00 2019-Sep 20190901 |
PublicationDateYYYYMMDD | 2019-09-01 |
PublicationDate_xml | – month: 09 year: 2019 text: September 2019 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Journal of cellular physiology |
PublicationTitleAlternate | J Cell Physiol |
PublicationYear | 2019 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | e_1_2_7_1_10_1 e_1_2_7_1_11_1 e_1_2_7_1_12_1 e_1_2_7_1_13_1 e_1_2_7_1_30_1 e_1_2_7_1_5_1 Wei H. (e_1_2_7_1_24_1) 2013; 17 e_1_2_7_1_29_1 e_1_2_7_1_6_1 Shibaji T. (e_1_2_7_1_18_1) 2003; 23 Erickson L. A. (e_1_2_7_1_7_1) 2015; 9 e_1_2_7_1_8_1 e_1_2_7_1_25_1 e_1_2_7_1_2_1 e_1_2_7_1_26_1 e_1_2_7_1_3_1 e_1_2_7_1_27_1 e_1_2_7_1_4_1 e_1_2_7_1_28_1 e_1_2_7_1_21_1 e_1_2_7_1_22_1 e_1_2_7_1_23_1 e_1_2_7_1_9_1 e_1_2_7_1_20_1 e_1_2_7_1_19_1 e_1_2_7_1_14_1 e_1_2_7_1_15_1 e_1_2_7_1_16_1 e_1_2_7_1_17_1 |
References_xml | – ident: e_1_2_7_1_13_1 doi: 10.3892/mmr.2015.3144 – volume: 9 start-page: 2029 year: 2015 ident: e_1_2_7_1_7_1 article-title: Targeting the hypoxia pathway to treat pancreatic cancer publication-title: Drug Design, Development and Therapy – volume: 17 start-page: 436 issue: 4 year: 2013 ident: e_1_2_7_1_24_1 article-title: Effects of the silencing of hypoxia‐inducible factor‐1 alpha on metastasis of pancreatic cancer publication-title: European Review for Medical and Pharmacological Sciences – ident: e_1_2_7_1_3_1 doi: 10.1038/onc.2015.325 – ident: e_1_2_7_1_23_1 doi: 10.1089/ars.2007.1628 – ident: e_1_2_7_1_21_1 doi: 10.18632/oncotarget.8834 – ident: e_1_2_7_1_25_1 doi: 10.1002/jcb.25988 – ident: e_1_2_7_1_27_1 doi: 10.2478/s11658-014-0212-6 – ident: e_1_2_7_1_22_1 doi: 10.1016/j.bbrc.2011.04.035 – ident: e_1_2_7_1_28_1 doi: 10.3892/ol.2013.1620 – ident: e_1_2_7_1_9_1 doi: 10.1093/ije/dyx232 – ident: e_1_2_7_1_15_1 doi: 10.1007/978-1-4939-3378-5_21 – ident: e_1_2_7_1_17_1 doi: 10.1016/j.cell.2011.07.014 – ident: e_1_2_7_1_10_1 doi: 10.1016/j.biopha.2017.08.057 – ident: e_1_2_7_1_20_1 doi: 10.1177/1535370214555665 – ident: e_1_2_7_1_6_1 doi: 10.1007/s11010-013-1795-3 – ident: e_1_2_7_1_8_1 doi: 10.1586/17474124.2016.1117386 – ident: e_1_2_7_1_11_1 doi: 10.1016/S0360-3016(00)00803-8 – ident: e_1_2_7_1_14_1 doi: 10.1242/bio.021774 – ident: e_1_2_7_1_5_1 doi: 10.1016/j.ctrv.2017.08.007 – ident: e_1_2_7_1_16_1 doi: 10.1097/MPA.0000000000000389 – ident: e_1_2_7_1_29_1 doi: 10.1038/s41419-017-0052-1 – ident: e_1_2_7_1_4_1 doi: 10.18632/oncotarget.7168 – ident: e_1_2_7_1_26_1 doi: 10.1016/j.biopha.2017.11.113 – volume: 23 start-page: 4721 issue: 6 year: 2003 ident: e_1_2_7_1_18_1 article-title: Prognostic significance of HIF‐1 alpha overexpression in human pancreatic cancer publication-title: Anticancer Research – ident: e_1_2_7_1_2_1 doi: 10.2174/187152011795677463 – ident: e_1_2_7_1_12_1 doi: 10.1186/s12943-017-0588-9 – ident: e_1_2_7_1_19_1 doi: 10.4238/gmr15048936 – ident: e_1_2_7_1_30_1 doi: 10.1177/1533034616665720 |
SSID | ssj0009933 |
Score | 2.4485993 |
Snippet | Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment‐resistant phenotype induced by the extent of... Nowadays, pancreatic cancer (PC) remains the most lethal tumor, partially due to the invasive and treatment-resistant phenotype induced by the extent of... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 15407 |
SubjectTerms | Biotechnology Cancer Cell growth Cell proliferation Epidermal growth factor receptors FEZF1‐AS1 Hypoxia invasion Invasiveness Kinases miR‐133a/EGFR miR‐142/HIF‐1α Pancreatic cancer Phenotypes Ribonucleic acid RNA Signal transduction Tumors Vascular endothelial growth factor |
Title | Long noncoding RNA FEZF1‐AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR‐142/HIF‐1α and miR‐133a/EGFR upon hypoxia/normoxia |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.28188 https://www.ncbi.nlm.nih.gov/pubmed/30693518 https://www.proquest.com/docview/2229848518 https://www.proquest.com/docview/2179446033 |
Volume | 234 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ditQwFA7LguCNP7v-jK4SRWRvOtMmaafFq2GZOi66yOjCIkJJMomO7rRlOiOOVz6Cr-K9z-BD-CSek_4s6w-Id6E5aZr0nORLcvIdQh4Ywy0MedKL_ER6QiXcU4xJj5kkYZLB-sfiReFnR9HkWByehCdb5FF7F6bmh-g23NAy3HiNBi5VNTgjDX2nyz5SGeFFX_TVQkA0PaOOSpow8s4FIRRByyrks0FX8vxc9BvAPI9X3YSTXiav20-t_Uze99cr1deffmFx_M-2XCGXGiBKR7XmXCVbJt8hu6McFuGLDX1InWuo23PfIRfqiJWbXfLtaZG_oXmR6wInPTo9GtF0_CoNfnz-MnoR0HKJBz-ripZFsaTo_JUX1byiMp_RRTHDWGEGMkHVHFjVVKPWLSmeH6D4KXraOGVxReb5B4nbebQJJ0QX8ynUFAg2mDxJMfX9a_3u-jnncjB-nE7puoRCbzdl8XEuBzngckxcI8fp-OXBxGsCQHiaRWDBImQi9C2AUi25jSOlAhPDm8Kh9LkOjDDMJtHQAsRKmA25tUZGQQygMfKF8i2_TrahR8xNAq1JAiutsXzGhQmFEmJoIyW0igFzCdMj-60qZLphR8cgHadZzevMMvhHmftHPXK_Ey1rSpA_Ce21-pQ1o0KVYez0WADGhex7XTbYM3ayzE2xBhkcIUXkc94jN2o97GqB5V3CXel9p01_rz47PHjuErf-XfQ2uQhosHGg2yPbq-Xa3AHEtVJ3nWn9BNjwK2U |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVKEaIvXFouCwUMQqgv2SS2k00kXlZlw7ZsV2hppQoJRU7WLgvdJNoLYnniE_gV3vkGPoIvYca5VOUiId6seGzH8Yx9bE_OEPJYKa5hypOW74TSEknIrYQxaTEVhkwy2P9o_FH4YOj3j8T-sXe8Rp7W_8KU_BDNgRtahpmv0cDxQNo-Yw19lxZt5DIKLpCLGNEbmfOfjc7Io8IqkLxxQvCEW_MKOcxuip5fjX6DmOcRq1lyoqvkTf2ypafJ-_ZykbTTT7_wOP5vb66RKxUWpd1Sea6TNZVtkq1uBvvw6Yo-ocY71By7b5JLZdDK1Rb5NsizE5rlWZrjukdHwy6Neq8j98fnL91XLi1mePezmNMiz2cU_b-yfD6ZU5mN6TQfY7gwBZmgbQavpjRFxZtRvEJA8VN0tjH6YopMsg8ST_RoFVGITicjaMkVzO7vRZj6_rWsu3zOubR7z6MRXRZQ6O2qyD9OpJ0BNMfEDXIU9Q53-1YVA8JKmQ9GLDwmPEcDLk0l14GfJK4KoCavIx2eukoopkO_owFlhUx7XGslfTcA3Og7InE0v0nW4Yuo2wR6E7paaqX5mAvliUSIjvYTkSYBwC6hWmSn1oU4rQjSMU7HaVxSO7MYxig2Y9QijxrRomQF-ZPQdq1QcTUxzGMMnx4IgLmQ_bDJBpPGjywzlS9BBidJ4Tuct8itUhGbVmCHF3JTeseo09-bj_d3X5rEnX8XfUAu9w8PBvFgb_jiLtkAcFj5022T9cVsqe4BAFsk942d_QRkYC-B |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLVKEYgNj5bHQAGDEOomk8R2MolYjdoJ01JG1UClCiFFtseGgY4TzQMxrPgEfoU938BH8CVcO8lU5SEhdlZ8Hedxrn3s3JyL0COlqIYhj3txkHKPiZR6ghDuEZWmhBNY_2j7o_DzQdw_YvvH0fEaetL8C1PpQ6w23KxnuPHaOng50v6paOg7WbatlFFyDp1n0JPN27A7PNWOSus88i4GIWJhIysUEH_V9Oxk9BvDPEtY3YyTXUGvm2utAk3etxdz0ZaffpFx_M-buYou10wUdyvoXENrymygza6BVfhkiR9jFxvqNt030IUqZeVyE307KMwbbAojCzvr4eGgi7Peqyz88flL90WIy6n98jOf4bIopthGf5liNp5hbkZ4UoxssjAFlYA1x1YllhZ2U2w_IFjzExtq49DimozNB27383CdTwhPxkPoKWTE7-9ltvT9a3Xu6jil3O89zYZ4UUKjt8uy-DjmvgFibgvX0VHWe7nT9-oMEJ4kMbgwiwiLAg2sVHKqk1iIUCVwpqjDAypDxRTRadzRwLFSoiOqteJxmABrjAMmAk1voHV4IuoWgrtJQ8210nREmYqYYKyjY8GkSIB0MdVC2w0UclnLo9ssHSd5JexMcnhHuXtHLfRwZVpWmiB_Mtpq8JTXw8Ist8nTEwYkF6ofrKrBoe1D5kYVC7CxQyQAmtIWulnhcNULrO9S6lpvOzT9vft8f-fQFW7_u-l9dPFwN8sP9gbP7qBLwAzrYLottD6fLtRdYF9zcc952U-_ZC4w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long+noncoding+RNA+FEZF1%E2%80%90AS1+predicts+poor+prognosis+and+modulates+pancreatic+cancer+cell+proliferation+and+invasion+through+miR%E2%80%90142%2FHIF%E2%80%901%CE%B1+and+miR%E2%80%90133a%2FEGFR+upon+hypoxia%2Fnormoxia&rft.jtitle=Journal+of+cellular+physiology&rft.au=Ou%2C+Zheng%E2%80%90Lin&rft.au=Zhang%2C+Min&rft.au=Ji%2C+Lian%E2%80%90Dong&rft.au=Luo%2C+Zhen&rft.date=2019-09-01&rft.issn=0021-9541&rft.eissn=1097-4652&rft.volume=234&rft.issue=9&rft.spage=15407&rft.epage=15419&rft_id=info:doi/10.1002%2Fjcp.28188&rft.externalDBID=10.1002%252Fjcp.28188&rft.externalDocID=JCP28188 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon |